These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 7792878)

  • 1. Chronic rejection in kidney transplant patients receiving cytomegalovirus prophylaxis with acyclovir.
    Birkeland SA; Rohr N; Elbirk A; Jørgensen KA
    Transplant Proc; 1995 Jun; 27(3):2040-1. PubMed ID: 7792878
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of combination prophylaxis with cytomegalovirus hyperimmune globulin and acyclovir in the high-risk kidney transplant recipient.
    Uber L; Cofer J; Baliga P; Rajagopalan PR
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):42-3. PubMed ID: 7482818
    [No Abstract]   [Full Text] [Related]  

  • 3. Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: a case-controlled study.
    Legendre C; Ducloux D; Ferroni A; Chkoff N; Valette C; Geffrier C; Rouzioux C; Kreis H
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1431-3. PubMed ID: 8382871
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival.
    Abraham KA; O'Kelly P; Spencer S; Hickey DP; Conlon PJ; Walshe JJ
    Ren Fail; 2008; 30(2):141-6. PubMed ID: 18300112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial.
    Pouteil-Noble C; Megas F; Chapuis F; Bosshard S; Colin C; Hadj-Aissa A; Pozet N; Martin X; Lefrançois N; Garnier JL; Aymard M; Touraine JL
    Transplant Proc; 1996 Oct; 28(5):2811. PubMed ID: 8908072
    [No Abstract]   [Full Text] [Related]  

  • 7. Ganciclovir/acyclovir prophylaxis reduces the incidence of cytomegalovirus infections in pancreas transplant recipients.
    Harland RC; Vernon WB; Bunzendahl H; Thompson JK; Lawrence C; Bollinger RR
    Transplant Proc; 1994 Apr; 26(2):432-3. PubMed ID: 8171488
    [No Abstract]   [Full Text] [Related]  

  • 8. Incidence of infection and acute rejection after cytomegalovirus immune globulin prophylaxis in renal transplantation.
    Basadonna G; Feria A; Perez R; Klein H; Sturges M; Colquhoun S
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):52-3. PubMed ID: 7940976
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytomegalovirus prophylaxis in antibody-treated renal transplanted patients.
    Birkeland S; Gahrn-Hansen B; Andersen H; Rohr N; Larsen KE; Jørgensen A
    Transplant Proc; 1995 Dec; 27(6):3473-6. PubMed ID: 8540056
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytomegalovirus infections in the immunocompromised transplant patient. Prevention of cytomegalovirus disease with oral acyclovir.
    Balfour HH; Fletcher CV; Dunn D
    Transplant Proc; 1991 Apr; 23(2 Suppl 1):17-9. PubMed ID: 1647558
    [No Abstract]   [Full Text] [Related]  

  • 11. Cytomegalovirus disease prophylaxis in seronegative recipients of kidneys from seropositive donors by combination of cytomegalovirus-hyperimmune globulin and low-dose acyclovir.
    MacDonald AS; Belitsky P; Cohen A; Lee S
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1355-6. PubMed ID: 1846463
    [No Abstract]   [Full Text] [Related]  

  • 12. Cytomegalovirus infection in pediatric kidney transplantation.
    Fontana I; Verrina E; Timitilli A; Arcuri V; Basile G; Losurdo G; Rabagliati AM; Perfumo F; Giacchino R; Gusmano R
    Transplant Proc; 1994 Feb; 26(1):18-9. PubMed ID: 8108929
    [No Abstract]   [Full Text] [Related]  

  • 13. Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective?
    Goral S; Ynares C; Dummer S; Helderman JH
    Kidney Int Suppl; 1996 Dec; 57():S62-5. PubMed ID: 8941924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Open clinical trial with oral acyclovir for the prophylaxis of disease by Cytomegalovirus in low risk liver transplant recipients].
    Moreno J; Montero JL; Gavilán F; Costán G; Herrero C; Cárdenas M; Sánchez-Guijo P; Torre-Cisneros J
    Enferm Infecc Microbiol Clin; 1999 Oct; 17(8):382-5. PubMed ID: 10563084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elimination of cytomegalovirus disease in liver transplant patients treated prophylactically with combination cytomegalovirus hyperimmune globulin and ganciclovir.
    Prian GW; Koep LJ
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):54-5. PubMed ID: 7940977
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ; Busuttil RW
    Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economic value of valacyclovir prophylaxis in transplantation.
    Squifflet JP; Legendre C
    J Infect Dis; 2002 Oct; 186 Suppl 1():S116-22. PubMed ID: 12353196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
    J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acyclovir to prevent cytomegalovirus infection in renal-graft recipients.
    Grundy JE; Griffiths PD
    N Engl J Med; 1989 Nov; 321(18):1268-9. PubMed ID: 2552315
    [No Abstract]   [Full Text] [Related]  

  • 20. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation.
    Fiddian P; Sabin CA; Griffiths PD
    J Infect Dis; 2002 Oct; 186 Suppl 1():S110-5. PubMed ID: 12353195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.